Affimed NV (NASDAQ:AFMD) recently disclosed that it has entered a clinical research partnership with Merck & Co., Inc. (NYSE:MRK) in terms of immune-oncology treatment. As per the agreement, Affimed will conduct a Phase 1b clinical trial with a combination of Keytruda—Merck’s anti-PD-1 therapy—with its own AFM13, for Hodgkin’s Lymphoma patients. These include patients who were not affected by chemotherapy, which includes treatment with antibody-drug-conjugate Adcetris—a renowned drug in the market.
Merck will supply its drug to Affimed for the clinical trial. The trial’s main purpose is to build a proper dosing regimen for the drug combination, and to test its safety and efficacy. The study is expected to commence in the first half of calendar year 2016 (1HCY16).
Previously, Affimed witnessed some management changes. It announced Joerg Windisch’s appointment as the new COO, and that Bernhard Ehmer has been included in the Supervisory Board. Mr. Ehmer has extensive clinical development track record in biopharmaceuticals. The company’s shareholders approved the new appointments at the Extraordinary Shareholder Meeting, held on January 21, 2016 in Amsterdam.
Affimed Teams up with Merck to Combat Hodgkin's Lymphoma
Affimed NV (NASDAQ:AFMD) has announced a new partnership with Merck & Co., Inc. (NYSE:MRK) to conduct trials for a combination of both companies' key candidates for Hodgkin's Lymphoma.
No comments:
Post a Comment